Access to Medical Treatment Act provisions questioned by FDA's Friedman at hearing.
This article was originally published in The Tan Sheet
Executive Summary
UNAPPROVED THERAPY SAFETY/EFFICACY BURDEN OF PROOF SHIFT TO FDA under the Access to Medical Treatment Act (HR 746) is one of several objections the agency has to the bill as drafted, FDA Lead Deputy Director Michael Friedman, MD, testified at a House Government Reform & Oversight Committee hearing April 22. In written comments to Chairman Dan Burton's (R-Ind.) committee, Friedman outlined a number of "significant concerns" the agency has with the bill.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning